AVROBIO, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
AVRO Company Description
Avrobio Inc is a clinical-stage gene therapy company. The company is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single-dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.
AVRO Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view AVRO Smart Score
Score Breakdown
AVRO Company Description
Show More
Avrobio Inc is a clinical-stage gene therapy company. The company is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single-dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of AVRO by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by AVRO's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of AVRO in WallStreetBets Daily Discussion
AVRO News
Recent insights relating to AVRO
CNBC Recommendations
Recent picks made for AVRO stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in AVRO
Corporate Flights
Flights by private jets registered to AVRO
Our Analysis